Page last updated: 2024-12-05

qx-222

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

QX-222: amphipathic amine; RN given refers to ion; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5014
CHEMBL ID1354145
CHEBI ID92720
SCHEMBL ID94463
MeSH IDM0048144

Synonyms (23)

Synonym
tocris-1043
NCGC00015597-01
NCGC00024960-01
lopac-l-1788
LOPAC0_000707
NCGC00024960-02
qx-222
2-[(2,6-dimethylphenyl)amino]-n,n,n-trimethyl-2-oxoethanaminium
21236-55-5
[2-(2,6-dimethylanilino)-2-oxoethyl]-trimethylazanium
CCG-204792
2-((2,6-dimethylphenyl)amino)-n,n,n-trimethyl-2-oxoethanaminium
ethanaminium, 2-((2,6-dimethylphenyl)amino)-n,n,n-trimethyl-2-oxo-
NCGC00015597-02
NCGC00015597-03
BRD-K40782193-003-01-1
SCHEMBL94463
CHEMBL1354145
CHEBI:92720
[2-(2,6-dimethylanilino)-2-oxoethyl]-trimethylammonium
Q27164437
DTXSID90943654
2-[(2,6-dimethylphenyl)imino]-2-hydroxy-n,n,n-trimethylethan-1-aminium

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"A method for carrying out dose-response studies of ion channel currents in cell-attached patches has been devised."( Single-channel dose-response studies in single, cell-attached patches.
Auerbach, A, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency11.22020.02827.055915.8489AID895; AID928
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.35480.00106.000935.4813AID943
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (26.92)18.7374
1990's21 (40.38)18.2507
2000's9 (17.31)29.6817
2010's6 (11.54)24.3611
2020's2 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.61 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (96.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]